Use of EBPT in Critically Ill Patients With AKI and/or Multiorgan Failure
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorCareggi Hospital
About this trial
The use of extracorporeal blood purification therapies (EBPT) is becoming increasingly widespread worldwide in everyday clinical practice, particularly in the critical care setting. Nonetheless, most of the clinical trials aimed at exploring the effect of EBPT on patients' long-term outcomes have failed to demonstrate consistent results regarding 28 day- or hospital- mortality rates. The aim of this observational prospective registry is to evaluate if there is a cluster of critically ill patients that mostly benefits from extracorporeal blood purification therapies with different EBPTs.
Eligibility criteria
Qualifiers
critically ill patients in the ICU
CRRT/IHD/Hybrid therapies for support//replacement renal function
immunomodulation achieved by "high cut-off membranes", "endotoxins and/or cytokines adsorbent membranes" or by high-volume hemofiltration
Disqualifiers
patients treated only by Cytosorb® and/or Toraymyxin® therapies
Trial design
Treatments tested in this trial
- Commercial membrane for Extracorporeal Blood Purification Therapy (EBPT)
Treatment groups
1,000 Participants
are divided into 1 treatment groupSponsors and collaborators
Careggi Hospital
Lead sponsor
University of Florence
Collaborator
Source ClinicalTrials.gov